The regenerative biostimulator
that renews skin from within 1-6

Over time, we may feel we don’t look like we used to

That our face has started to sag and our skin looks dull and tired.

Sculptra® is a regenerative treatment

The first proven regenerative biostimulator.

Sculptra® helps address multiple skin concerns1,5,15-18 while delivering progressive, natural-looking, and long-lasting results for more than 2 years.2-4, 6-11

Whether you are looking for:


  • Improved skin quality for a radiant, youthful glow 6, 13, 27
  • Renewed volume 2, 6, 12, 27

  • 89%

    patients who reported improvement in skin firmness 2 years after treatment6

  • 91%

    patients who reported an improvement in skin radiance (glow) 2 years after treatment6

  • 86%

    of patients maintained enhanced jawline definition 2 years after treatment6

Before & After photos

See More Results

Sculptra®

The first proven regenerative biostimulator

Sculptra® is the first proven regenerative biostimulator that helps restore the skin’s structure.1,5,6,15-19

It stimulates collagen and elastin, strengthening your skin’s foundation, increasing its healthy thickness and restoring firmness over time.2-4, 7, 11, 12-13, 20-23

Rejuvenated, firm and radiant skin lasting more than 2 years2,6,24

Stay true to you! Sculptra® works progressively by increasing your own collagen and elastin,1-4,7,11,12-13.20-23 with visible results already 1 month after treatment and that last for more than 2 years.1-2,4,6

The Science Behind

Find a Specialist

Achieve the look you envision by speaking to a healthcare practitioner today.

Get Started

Frequently asked questions

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam mollis placerat molestie. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

One of the best things about Sculptra® is how long it lasts. The treatment provides rejuvenated skin for more than 2 years.2,4,6

Morbi dictum, turpis quis vulputate aliquet, odio nisi pellentesque purus, in sollicitudin metus erat sed felis. Maecenas ullamcorper finibus pretium.

Skin Trends

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor

More Skin Trends

References

  1. Sculptra® EU MDR IFU
  2. Brandt FS, et al. Aesthet Surg J. 2011;31(5):521–8.
  3. Fabi S, et al. Dermatol Surg. 2024;50:1137–42.
  4. Narins RS, et al. J Am Acad Dermatol. 2010;62(3):448–62.
  5. Widgerow A, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic Acid (PLLA-SCA™) and calcium hydroxylapatite (CaHA) in the treatment of nasolabial folds. Poster, IMCAS World Congress, 1–3 Feb 2024, Paris.
  6. Fabi S, et al. Poster: Effectiveness and safety of correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant—clinical study data up to 24 months. IMCAS World Congress, 26–28 Jan 2023, Paris.
  7. Huth S, et al. J Drugs Dermatol. 2024;23(4):285–8.
  8. FDA. Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf3/ p030050s002b.pdf. Accessed (2022 Nov).
  9. Galderma. Data on file (MA-54151).
  10. Galderma. Data on file (MA-46589).
  11. Goldberg D, et al. Dermatol Surg. 2013;39(6):915–22.
  12. Valantin MA, et al. AIDS. 2003;17(17):2471–7.
  13. Bohnert K et al. Dermatol Surg. 2019; 45(5):718–24.
  14. Galderma. Data on file (MA-50526).
  15. Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners. Galderma. 2021. Available from: https://www.galderma.com/news/galderma-receives-fda-approvalnew-sculptra-label-offering-more-options-aesthetic-partners [Last accessed June 2024].

Job code: UKI-SCU-2600005 Date of Preparation: March 2026

AE Statement: Adverse events should be reported.

For the UK, Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Website: www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd, Email: medinfo.uk@galderma.com, Tel: +44 (0) 300 3035674

Other Disclaimers: ‘Individual results may vary’